We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+9.98%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$846M
AUM Growth
-$143M
Cap. Flow
-$121M
Cap. Flow %
-14.33%
Top 10 Hldgs %
70.39%
Holding
52
New
24
Increased
5
Reduced
10
Closed
6

Top Buys

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$47.4M
2
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$36.8M
3
TGTX icon
TG Therapeutics
TGTX
+$19.2M
4
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$18.7M
5
LRMR icon
Larimar Therapeutics
LRMR
+$13.8M

Top Sells

Rank Stock Value
1
ACHN
Achillion Pharmaceuticals
ACHN
+$147M
2
ENTA icon
Enanta Pharmaceuticals
ENTA
+$51.4M
3
RPRX
Repros Therapeutics Inc.
RPRX
+$21.1M
4
DYAX
DYAX CORPORATION
DYAX
+$21.1M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$20.5M

Sector Composition

Rank Sector Weight
1 Healthcare 49.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTO
26
DELISTED
Altamira Therapeutics Ltd
CYTO
$5.42M 0.64%
+12
New +$5.94M
TTOO
27
DELISTED
T2 Biosystems, Inc
TTOO
$2.5M 0.29%
+28
New +$2.61M
WGBS
28
DELISTED
WaferGen Bio-systems, Inc.
WGBS
$2.44M 0.29%
+112,000
New +$2.5M
OCRX
29
DELISTED
Ocera Therapeutics, Inc.
OCRX
$2.05M 0.24%
417,476
-73,221
-15% -$423K
ALIM
30
DELISTED
Alimera Sciences
ALIM
$1.32M 0.16%
16,248
-28,196
-63% -$2.41M
CDXS icon
31
Codexis
CDXS
$158M
$1.18M 0.14%
+504,279
New +$1.08M
PTCT icon
32
PTC Therapeutics
PTCT
$6.18B
$1.14M 0.13%
+25,800
New +$807K
AGIO icon
33
Agios Pharmaceuticals
AGIO
$2.08B
$1.08M 0.13%
+17,600
New +$759K
VRTX icon
34
Vertex Pharmaceuticals
VRTX
$123B
$1.04M 0.12%
+9,300
New +$885K
MACK
35
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$1.02M 0.12%
+14,794
New +$791K
RGEN icon
36
Repligen
RGEN
$6.91B
$896K 0.11%
+45,000
New +$947K
REGN icon
37
Regeneron Pharmaceuticals
REGN
$72.9B
$883K 0.1%
+2,450
New +$821K
BIIB icon
38
Biogen
BIIB
$30.9B
$860K 0.1%
+2,600
New +$857K
AMGN icon
39
Amgen
AMGN
$209B
$829K 0.1%
+5,900
New +$770K
CELG
40
DELISTED
Celgene Corp
CELG
$825K 0.1%
+8,700
New +$785K
ALKS icon
41
Alkermes
ALKS
$8.11B
$823K 0.1%
+19,200
New +$861K
KERX
42
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$814K 0.1%
+59,200
New +$906K
KYTH
43
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$745K 0.09%
+22,750
New +$801K
ACAD icon
44
Acadia Pharmaceuticals
ACAD
$4.51B
$743K 0.09%
+30,000
New +$702K
PBYI icon
45
Puma Biotechnology
PBYI
$398M
$740K 0.09%
+3,100
New +$637K
LUMO
46
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$643K 0.08%
+3,333
New +$733K
ARWR icon
47
Arrowhead Research
ARWR
$12.1B
– –
-604,346
Closed -$8.65M
ATHE
48
CALL
Alterity Therapeutics
ATHE
$80.5M
– –
-1,667
Closed -$227K
EYPT icon
49
EyePoint Inc
EYPT
$999M
– –
-255,566
Closed -$11.1M
NBIX icon
50
Neurocrine Biosciences
NBIX
$18.2B
– –
-68,968
Closed -$1.02M
1
2
3

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q3 2014 Portfolio in Review

As of Q3 2014, RA Capital Management held 52 positions worth $846M, down 14% from $989M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

RA Capital Management withdrew a net $121M in Q3 2014, closing 6 positions and reducing 10 holdings. Its most notable exit was Repros Therapeutics Inc., an estimated $21.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 60% a quarter earlier.

Against the trend, RA Capital Management opened a new position in AVANIR PHARMACEUTICALS, INC CL A worth $64.2M.

  • RA Capital Management's largest Q3 2014 buy was AVANIR PHARMACEUTICALS, INC CL A: 5,386,700 shares worth $64.2M.
  • RA Capital Management added most to BioCryst Pharmaceuticals in Q3 2014, an estimated $47.4M increase.
  • RA Capital Management's biggest Q3 2014 reduction was Achillion Pharmaceuticals, cutting an estimated $147M.
  • RA Capital Management fully exited Repros Therapeutics Inc. in Q3 2014, selling an estimated $21.1M.
  • RA Capital Management's ten largest holdings make up 70% of its $846M portfolio in Q3 2014.
  • RA Capital Management opened 24 new positions and closed 6 in Q3 2014.
  • RA Capital Management's portfolio value fell 14% quarter-over-quarter to $846M.

Based on RA Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.